The synthetic antimicrobial peptide SET-M33 is being developed as a possible new antibacterial candidate for the treatment of multi-drug resistant bacteria. SET-M33 is a branched peptide featuring higher resistance and bioavailability than its linear analogues. SET-M33 shows antimicrobial activity against different species of multi-resistant Gram-negative bacteria, including clinically isolated strains of Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumanii and Escherichia coli. The secondary structure of this 40 amino acid peptide was investigated byNMRto fully characterize the product in the framework of preclinical studies. The possible presence of helixes or β-sheets in the structure had to be explored to predict the behavior of the branched peptide in solution, with a view to designing a formulation for parenteral administration. Since the final formulation of SET-M33 will be strictly defined in terms of counter-ions and additives, we also report the studies on a new salt form, SET-M33 chloride, that retains its activity against Gram-negative bacteria and gains in solubility, with a possible improvement in the pharmacokinetic profile. The opportunity of using a chloride counter-ion is very convenient from a process development point of view and did not increase the toxicity of the antimicrobial drug.

Castiglia, F., Zevolini, F., Riolo, G., Brunetti, J., De Lazzari, A., Moretto, A., et al. (2019). NMR study of the secondary structure and biopharmaceutical formulation of an active branched antimicrobial peptide. MOLECULES, 24(23), 1-13 [10.3390/molecules24234290].

NMR study of the secondary structure and biopharmaceutical formulation of an active branched antimicrobial peptide

Castiglia F.;Zevolini F.;Riolo G.;Brunetti J.;Bracci L.;Pini A.
2019-01-01

Abstract

The synthetic antimicrobial peptide SET-M33 is being developed as a possible new antibacterial candidate for the treatment of multi-drug resistant bacteria. SET-M33 is a branched peptide featuring higher resistance and bioavailability than its linear analogues. SET-M33 shows antimicrobial activity against different species of multi-resistant Gram-negative bacteria, including clinically isolated strains of Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumanii and Escherichia coli. The secondary structure of this 40 amino acid peptide was investigated byNMRto fully characterize the product in the framework of preclinical studies. The possible presence of helixes or β-sheets in the structure had to be explored to predict the behavior of the branched peptide in solution, with a view to designing a formulation for parenteral administration. Since the final formulation of SET-M33 will be strictly defined in terms of counter-ions and additives, we also report the studies on a new salt form, SET-M33 chloride, that retains its activity against Gram-negative bacteria and gains in solubility, with a possible improvement in the pharmacokinetic profile. The opportunity of using a chloride counter-ion is very convenient from a process development point of view and did not increase the toxicity of the antimicrobial drug.
2019
Castiglia, F., Zevolini, F., Riolo, G., Brunetti, J., De Lazzari, A., Moretto, A., et al. (2019). NMR study of the secondary structure and biopharmaceutical formulation of an active branched antimicrobial peptide. MOLECULES, 24(23), 1-13 [10.3390/molecules24234290].
File in questo prodotto:
File Dimensione Formato  
NMR Study of the Secondary Structure-2019.pdf

accesso aperto

Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 2.82 MB
Formato Adobe PDF
2.82 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1105144